Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay
Executive Summary
US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.
You may also be interested in...
Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Of the 27 suits brought so far, four have resulted in patent settlements; restarting patent dance is new trend for ongoing litigation.
Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Of the 27 suits brought so far, four have resulted in patent settlements; restarting patent dance is new trend for ongoing litigation.
US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017
For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.